Tag: oncology

Randomized Clinical Trials Shown to Accurately Predict Real-World Overall Survival

New Study Compares Clinical Trial Efficacy and Real-World Effectiveness of Therapies for Breast, Colorectal, Lung, Ovarian, and Pancreatic Cancers Princeton, NJ—July 26, 2017—Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), announced today

Posted in Announcements, ISPOR News & Press, Uncategorized Tagged with: ,

New Methodological Approaches to Assess Value of Immuno-Oncology Therapies

Boston, MA—MAY 24, 2017—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) hosted a morning session at its 22nd Annual International Meeting in Boston, MA, USA that examined cost-effectiveness models for innovative oncology treatments.

Posted in Announcements, ISPOR News & Press Tagged with: , ,

New Research Findings: Health Costs for Children With Cancer Are Higher Than for Adolescents, Adults

Substantial Survival Gains in Children Mean That Treatment May Still Be Highly Cost Effective   Princeton, NJ—March 21, 2017—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today the publication of original research estimating the costs of cancer care

Posted in Announcements, ISPOR Journals, ISPOR News & Press, Value in Health Tagged with: , , , , ,

ISPOR 19TH ANNUAL EUROPEAN CONGRESS EXAMINES NEW APPROACHES TO SURVIVAL MODELING IN ONCOLOGY

Vienna, Austria—31 October 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held a workshop this afternoon on New Approaches to Survival Modeling in Oncology at the Society’s 19th Annual European Congress in Vienna, Austria. 

Posted in Announcements, ISPOR News & Press Tagged with: , ,

US HEALTH CARE SYSTEM BEGINS TO EMBRACE COST EFFECTIVENESS AS A CENTRAL COMPONENT OF “VALUE”

Value in Health Series Indicates We May Have Reached a Tipping Point  Princeton, NJ—August 29, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced today the publication of a series of articles suggesting that the application of cost-effectiveness analysis

Posted in Announcements, ISPOR Journals, ISPOR News & Press, Value in Health Tagged with: , , , , , , , , ,

ISPOR 21ST ANNUAL INTERNATIONAL MEETING ISSUE PANEL EXPLORES PATIENT PERSPECTIVES OF VALUE ASSESSMENT FRAMEWORKS IN ONCOLOGY

Washington, DC—May 25, 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual International Meeting Issue Panel 20—What Is the Value of Frameworks to Patients? The Case in Oncology—was held this morning in Washington, DC, USA.

Posted in Announcements, ISPOR News & Press Tagged with: , , , , , , ,

AUSTRALIA – CANCER DRUG REIMBURSEMENT ON PHASE 2 DATA

London, UK – Before a drug can be sold in Australia, it must receive approval from the regulator: the Therapeutic Goods Administration (TGA), typically requiring data from a large and lengthy Phase 3 randomized clinical trial. Public funding additionally requires

Posted in Health Policy Analyses Tagged with: , , ,

SHOULD COST-EFFECTIVENESS BE INCLUDED IN CLINICAL TREATMENT GUIDELINES?

At ISPOR’s Annual International Meeting, speakers addressed cost-effectiveness issues at both societal and patient levels Princeton, NJ, USA, May 19, 2015 – Oncology and cardiology professional organizations have embraced consideration of cost-effectiveness and the value of treatments in developing their

Posted in Announcements, ISPOR News & Press Tagged with: , , , , ,